Short answer
Amneal Pharmaceuticals, Inc. (AMRX) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation). $2.039B of term loans converted, plus $45.2M new borrowing to refinance nonconsenting lenders.
Amneal Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $2.039B of term loans converted, plus $45.2M new borrowing to refinance nonconsenting lenders
- Interest margins reduced 50 basis points to 1.50% base rate or 2.50% SOFR-based
- Estimated annualized cash interest savings of approximately $12M, supporting earnings and free cash flow
- August 1, 2032 maturity unchanged, limiting near-term refinancing relief
- Prepayment premium waived for repricing transactions after February 3, 2027
Item 2.03 · Creation of a Direct Financial Obligation
- Amendment No. 3 reprices Amneal’s term loan, potentially reducing borrowing costs and improving cash flow
- Effective August 3, 2026, with JPMorgan Chase Bank as administrative agent
- Revised debt terms may support deleveraging and liquidity, subject to the amendment’s detailed conditions
- Investors should review Exhibit 10.1 for interest-rate changes, savings estimates, covenants and maturity terms
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Amneal Pharmaceuticals, Inc. 8-K filings
Get the next AMRX 8-K as it lands
Follow AMRX for push alerts, or ask the research agent what this filing means.